Stroke RSS Page 6

Filtered By:
Specialty: Neurology
Drug: Pradaxa

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 127 results found since Jan 2013.

Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation Clinical Sciences
Conclusions— In real-world practice, dabigatran was associated with a reduced risk of ischemic stroke, intracranial hemorrhage, all hospitalized major bleeding, and all-cause mortality compared with warfarin in Asian patients with nonvalvular atrial fibrillation. Dabigatran did not increase the risk of major gastrointestinal bleeding or myocardial infarction compared with warfarin.
Source: Stroke - January 25, 2016 Category: Neurology Authors: Chan, Y.-H., Yen, K.-C., See, L.-C., Chang, S.-H., Wu, L.-S., Lee, H.-F., Tu, H.-T., Yeh, Y.-H., Kuo, C.-T. Tags: Atrial Fibrillation, Cardiovascular Disease, Race and Ethnicity, Intracranial Hemorrhage, Ischemic Stroke Clinical Sciences Source Type: research

Dabigatran Plasma Levels in Acute Cerebrovascular Events
Oral anticoagulation with dabigatran was shown to be effective for stroke prevention in patients with nonvalvular atrial fibrillation without the need for laboratory monitoring. However, a recent publication based on data of the Randomized Evaluation of Long-Term Anticoagulation Therapy study reported that ischemic stroke and bleeding outcomes are correlated with dabigatran plasma concentration (DPC). DPC was determined at a prespecified time point and correlated with cardiovascular events at any time during follow-up.
Source: Journal of Stroke and Cerebrovascular Diseases - January 22, 2016 Category: Neurology Authors: Bastian Volbers, Martin Köhrmann, Bernd Kallmünzer, Natalia Kurka, Lorenz Breuer, Jürgen Ringwald, Stefan Schwab Source Type: research

The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage
Conclusion In this small case series, reversal of NOAC with FEIBA was not associated with ICH expansion or any thrombotic or hemorrhagic complications.
Source: Neurocritical Care - November 6, 2015 Category: Neurology Source Type: research

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit-risk ratio
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of dabigatran in fixed-dosing regimens has indicated a small subgroup of patients that could be either over-treated, risking bleeding, or under-treated, risking embolism. Additional post-marketing data lends support to the favorable therapeutic profile of dabigatran but at the same time raises doubts about patient characteristics such as weight, age, renal function and their ...
Source: Therapeutic Advances in Neurological Disorders - October 27, 2015 Category: Neurology Authors: Safouris, A., Triantafyllou, N., Parissis, J., Tsivgoulis, G. Tags: Reviews Source Type: research

Design of Randomized, double‐blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE‐SPECT ESUS)
DiscussionAcetylsalicylic acid is the most common antithrombotic given to patients with embolic strokes of undetermined source to reduce recurrence risk. This trial will determine whether anticoagulation with dabigatran is more effective than acetylsalicylic acid, and acceptably safe.
Source: International Journal of Stroke - September 30, 2015 Category: Neurology Authors: Hans‐Christoph Diener, J. Donald Easton, Christopher B. Granger, Lisa Cronin, Christine Duffy, Daniel Cotton, Martina Brueckmann, Ralph L. Sacco, Tags: Protocol Source Type: research

Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants Clinical Sciences
Conclusions— If anti-Xa test is not available, we propose the use of the CoaguChek POCT to guide thrombolysis decisions after individual risk assessment in rivaroxaban-treated patients having acute ischemic stroke. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT02371044.
Source: Stroke - September 28, 2015 Category: Neurology Authors: Ebner, M., Peter, A., Spencer, C., Hartig, F., Birschmann, I., Kuhn, J., Wolf, M., Winter, N., Russo, F., Zuern, C. S., Blumenstock, G., Ziemann, U., Poli, S. Tags: Coagulation, Other anticoagulants, Other diagnostic testing, Emergency treatment of Stroke, Anticoagulants, Thrombolysis, Coagulation and fibronolysis Clinical Sciences Source Type: research

Intravenous thrombolysis in wake‐up stroke in a 92‐year‐old patient under dabigatran
Source: International Journal of Stroke - September 24, 2015 Category: Neurology Authors: Alessio Pieroni, Maria Luisa Capuana, Anne Falcou, Danilo Toni Tags: Letter to the editor Source Type: research

Dabigatran Therapy in Acute Ischemic Stroke Patients Without Atrial Fibrillation Brief Reports
Conclusions— Dabigatran treatment within 24 hours of minor stroke is feasible. A larger randomized trial is required to confirm the safety and efficacy of this treatment approach. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT 01769703.
Source: Stroke - August 24, 2015 Category: Neurology Authors: Kate, M., Gioia, L., Buck, B., Sivakumar, L., Jeerakathil, T., Shuaib, A., Butcher, K. Tags: Anticoagulants Brief Reports Source Type: research

Impact of dabigatran on platelet function and fibrinolysis
We sought to evaluate the potential enhanced fibrinolytic and antiplatelet activity of dabigatran etexilate (DE) due to decreased thrombin levels in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation (NVAF).
Source: Journal of the Neurological Sciences - July 22, 2015 Category: Neurology Authors: Argirios E. Tsantes, Elias Kyriakou, Stefanos Bonovas, Maria Chondrogianni, Christina Zompola, Chrissoula Liantinioti, Athina Simitsi, Aristeidis H. Katsanos, Maria Atta, Ignatios Ikonomidis, Violetta Kapsimali, Petros Kopterides, Georgios Tsivgoulis Source Type: research

Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection
ConclusionsIn this small, consecutive single‐center patient sample treating ischemic stroke patients with CeAD with NOACs did not bring up safety concerns and resulted in similar, good outcomes compared to patients using VKAs. Clinical, radiological, and outcome data in few stroke patients with cervical arterial dissection using nonvitamin K oral anticoagulants had no safety or efficacy concerns, having a good recanalization rate and outcome.
Source: Brain and Behavior - May 1, 2015 Category: Neurology Authors: Satu Mustanoja, Tiina M. Metso, Jukka Putaala, Noora Heikkinen, Elena Haapaniemi, Oili Salonen, Turgut Tatlisumak Tags: Original Research Source Type: research

Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Abstract Dabigatran, a direct thrombin inhibitor and activated factor X inhibitors, rivaroxaban and apixaban, used in the prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF), have several advantages over vitamin K antagonists (VKAs). The non-vitamin K oral anticoagulants (NOACs) have been shown to reduce the risk of intracranial bleedings by 50%. The current review summarizes the available data on the epidemiology, mechanisms and treatment of intracranial bleedings observed on oral anticoagulation with the focus on the specificity of NOACs in this context. PMID: 260...
Source: Neurologia i Neurochirurgia Polska - May 1, 2015 Category: Neurology Authors: Łukasik M, Zawilska K, Undas A Tags: Neurol Neurochir Pol Source Type: research

A dedicated Stroke Prevention in Atrial Fibrillation (SPAF) clinic for the acute assessment and initiation of anticoagulation in patients with atrial fibrillation. (P1.056)
CONCLUSIONS: This confirms the feasibility of a dedicated AF anticoagulation clinic and it’s ability to significantly increase anticoagulation rates among patients with AF. The intention is to expand this service to primary care initially through engagement in a cluster randomized trial (see next poster).Disclosure: Dr. Jolliffe has nothing to disclose. Dr. Rosemergy has nothing to disclose. Dr. Lanford has nothing to disclose. Dr. Abernethy has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Jolliffe, E., Rosemergy, I., Lanford, J., Abernethy, D. Tags: Cerebrovascular Disease and Interventional Neurology: Atrial Fibrillation and Cardio-embolic Stroke Source Type: research

Pages: 1 2 3 4 5 6 7 8 9